Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview

被引：0
作者：
Roberta Gualtierotti
Marco Parisi
Francesca Ingegnoli
机构：
[1] ASST Pini-CTO,Lupus Clinic, Department of Rheumatology and Medical Sciences
[2] University of Milan,Department of Clinical Sciences and Community Health
[3] ASST Santi Paolo e Carlo,Department of Orthopaedic Surgery and Traumatology, San Paolo Hospital
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Biological; DMARD; Inflammatory rheumatic diseases; Perioperative management; Rheumatoid arthritis; Systemic lupus erythematosus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with inflammatory rheumatic diseases often need orthopaedic surgery due to joint involvement. Total hip replacement and total knee replacement are frequent surgical procedures in these patients. Due to the complexity of the inflammatory rheumatic diseases, the perioperative management of these patients must envisage a multidisciplinary approach. The frequent association with extraarticular comorbidities must be considered when evaluating perioperative risk of the patient and should guide the clinician in the decision-making process. However, guidelines of different medical societies may vary and are sometimes contradictory. Orthopaedics should collaborate with rheumatologists, anaesthesiologists and, when needed, cardiologists and haematologists with the common aim of minimising perioperative risk in patients with inflammatory rheumatic diseases. The aim of this review is to provide the reader with simple practical recommendations regarding perioperative management of drugs such as disease-modifying anti-rheumatic drugs, corticosteroids, non-steroidal anti-inflammatory drugs and tools for a risk stratification for cardiovascular and thromboembolic risk based on current evidence for patients with inflammatory rheumatic diseases.
引用
收藏
页码：439 / 456
页数：17
相关论文
共 622 条
[41]  
Skredderstuen AK(2016)Novel oral therapies for psoriasis and psoriatic arthritis Am J Clin Dermatol 17 191-1026
[42]  
Fevang BT(2014)Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor Ann Rheum Dis 73 1020-54
[43]  
Mourao AF(2017)Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty Arthritis Care Res (Hoboken). 69 1845-3930
[44]  
Amaral M(2011)A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Arthritis Rheum 63 3918-731
[45]  
Caetano-Lopes J(2011)Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Lancet 377 721-716
[46]  
Isenberg D(2010)Off-label use of rituximab in systemic lupus erythematosus: a systematic review Clin Rheumatol 29 707-309
[47]  
Zangger P(2014)Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus J Rheumatol 41 300-461
[48]  
Esufali ZH(2011)Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis) Cochrane Database Syst Rev. 11 CD008872-1073
[49]  
Gladman DD(2002)Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis Rheumatology (Oxford) 41 458-6
[50]  
Bogoch ER(1998)Cyclooxygenase in biology and disease FASEB J. 12 1063-44
12345678910